GM23375-1, GM23375 clone 1
CBRCULi015-A
General
Donor Information
General Donor Information |
|
Sex | male |
Ethnicity | Caucasian, Iraqi |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Disease associated phenotypes |
|
Family history | The donor have a clinically affected mother. |
Is clinical information available? | Donor subject has one normal CTG repeat allele and one allele with a CTG repeat size of approximately 1700-1800 in the DMPK gene |
External Databases (Donor) |
|
BioSamples | SAMN00806757 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | https://www.coriell.org/ |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | |
Approval number | |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | |
Approval number | |
Is there an MTA available for the cell line? | Yes |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell line name | GM23375 |
Source cell type | |
Source cell line vendor | Coriell Institute for Medical Research |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Genes | |
Is reprogramming vector detectable? |
No |
Methods used |
PCR
|
Notes on reprogramming vector detection | The reprogramming vector is not detectable at passage 30. |
Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
Medium |
mTeSR™ Plus
|
Characterisation
Analysis of Undifferentiated Cells
Self-renewal
Negative
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Scorecard
Scorecard_CBRCULi015-A.jpg
Analysis of trilineage differentiation potential of CBRCULi015-A with the hPSC Scorecard
Differentiation Potency
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
XY normal
Passage number: P6
Karyotyping method:
Molecular karyotyping by SNP array
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.